Sponsors (7)
The bill tightens government authority and legal remedies related to mifepristone and preserves federal obscenity enforcement, but at the cost of substantially reducing access to medication abortion, increasing legal and economic risks for manufacturers and health providers, and imposing added burdens on public-health systems and courts.
State and federal enforcement authorities gain clearer power to prohibit marketing and interstate distribution of mifepristone within 14 days, making it easier for governments to restrict that medication.
People who oppose medication abortion (including some women and advocacy groups) will see reduced availability of mifepristone for termination of intrauterine pregnancy, aligning access with their policy preferences.
Individuals who claim bodily or mental-health harm from mifepristone can sue manufacturers for compensatory and punitive damages and recover attorney’s fees, increasing access to legal remedies.
Pregnant people seeking medication abortion will lose access to FDA-approved mifepristone products within 14 days, creating major new barriers that will delay care, force more invasive procedures, or require out‑of‑state travel.
Manufacturers may face large liability exposure and regulatory/legal risk, which could prompt suppliers to withdraw mifepristone from the U.S. market and block generics, reducing supply and driving up drug prices for patients and payers.
Hospitals, clinics, pharmacies, and manufacturers face criminal and enforcement risk for distributing or labeling products, risking supply disruptions and interruptions to reproductive health and related medical services.
Based on analysis of 8 sections of legislative text.
Withdraws FDA approval for mifepristone for terminating intrauterine pregnancy, treats its sale across state lines as unlawful/misbranded, and creates a federal civil cause of action against manufacturers.
Introduced March 11, 2026 by Joshua David Hawley · Last progress March 11, 2026
Removes federal approval for the drug mifepristone (used to terminate intrauterine pregnancy) and, shortly after enactment, treats introduction of that drug into interstate commerce as unlawful and its labeling as misbranded if it indicates use to terminate pregnancy. It also creates a new federal civil cause of action allowing people who claim bodily or mental-health harm from use of mifepristone to sue the drug's manufacturers for compensatory and punitive damages, plus attorney’s fees. The bill sets two different effective timelines: the regulatory withdrawal and misbranding rules take effect 14 days after enactment, and the private civil litigation remedy becomes available 90 days after enactment. It also preserves the continued application of 18 U.S.C. § 1461 despite other provisions in the Act.